While potentially protective, a pro-thrombotic effect from neutrophil cathepsin G might increase risk of pathologic thromboses in individuals with pre-existing pro-thrombotic states as has been described for patients with atherosclerosis [2]–[6] and myeloproliferative diseases [9]. Here, CTSG is linked to myeloproliferative disorder.